Medicure Inc
Medicure Inc. is a U.S.-focused pharmaceutical company that develops and commercializes prescription medicines and related healthcare products. Its business combines branded drug marketing with pharmacy operations through subsidiaries that serve patients, prescribers, long-term care facilities, and retail customers in the United States.
Liiketoiminta
Osuus liikevaihdostaPrescription medicines marketed and distributed in the U.S., including AGGRASTAT® and ZYPITAMAG®.
Prescription fulfillment, dispensing, and free home delivery through Marley Drug.
Pharmacy services for institutional and long-term care customers, including medication management.
Non-sterile compounding services provided through select pharmacy locations.
Asiakkaat
Medicure sells mainly to U.S. patients, prescribers, pharmacies, and healthcare organizations that need prescription medicines and dispensing services. Its branded drug business serves physicians and patients in cardiovascular and lipid-management treatment areas, while its pharmacy businesses serve retail customers, long-term care facilities, and patients needing delivery or compounding support.
Prescribers who choose AGGRASTAT® and ZYPITAMAG® for patients based on clinical need.
Patients filling prescriptions through Marley Drug for convenience and access.
Facilities buying pharmacy services and medication support for residents.
Customers using free delivery to receive medications directly at home.
Patients requiring non-sterile compounded medications from pharmacy locations.
Strategia
Medicure’s strategy centers on sustaining its branded pharmaceutical portfolio while using pharmacy subsidiaries to broaden access to medications and build recurring customer relationships. The company also uses local pharmacy locations and delivery capabilities to support patient access, institutional accounts, and service differentiation.
The branded drug portfolio is the core product base and drives physician and patient demand.
Delivery and local pharmacy services increase customer convenience and repeat prescriptions.
Long-term care accounts can provide recurring prescription volume and service depth.
Maantiede
Medicure’s business is centered in the United States, where its pharmaceuticals are marketed and its pharmacy operations serve all 50 states, Washington D.C., and Puerto Rico. The company also operates pharmacy locations in Portland, Oregon and Olympia, Washington, giving it a physical presence tied to local clinic and transportation networks.
Riskit
Medicure depends on a small set of prescription products and pharmacy operations, so concentration, competition, and reimbursement pressure can materially affect results. The company also faces regulatory, inventory, and estimation risks common to pharmaceutical and pharmacy businesses, including returns, chargebacks, rebates, and fair-value assumptions on obligations and contingent items.
- Product concentrationVaikutus: KorkeaTodennäköisyys: Korkea
The company’s commercial focus is centered on AGGRASTAT® and ZYPITAMAG®.
Kohdistuu: Branded pharmaceuticals
- Reimbursement and pricing pressureVaikutus: KorkeaTodennäköisyys: Korkea
Pharmacy and prescription drug businesses depend on payer and market pricing dynamics.
Kohdistuu: Retail and specialty pharmacy
- Regulatory complianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Prescription drugs and pharmacy operations are subject to healthcare and dispensing regulation.
Kohdistuu: U.S. pharmaceutical and pharmacy operations
- Revenue reserve estimatesVaikutus: KeskitasoTodennäköisyys: Korkea
Returns, chargebacks, rebates, and discounts require ongoing accrual estimates.
Kohdistuu: Branded pharmaceutical sales
- Fair value and royalty assumptionsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Royalty obligations and contingent items depend on valuation inputs and future revenue assumptions.
Kohdistuu: Financial liabilities and purchase obligations
Kirjanpito
Harkinnanvaraiset erätDrug sales often require estimates for returns, rebates, and chargebacks that can shift reported revenue.
Vaikutus: Branded pharmaceutical net sales
The liability uses expected future AGGRASTAT® revenue and discount-rate assumptions.
Vaikutus: Balance sheet liability and finance expense
Business-combination liabilities may move with valuation assumptions and trigger remeasurement gains or losses.
Vaikutus: Earnings volatility
The Sensible Medical investment is carried at fair value, so changes flow through results or OCI depending on classification.
Vaikutus: Comprehensive income and assets
IAS 34 interim statements increase reliance on estimates and can make quarter-to-quarter results less stable.
Vaikutus: Quarterly comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Exicure, Inc
XCUR · Pharmaceutical Preparations
Medifast Inc
MED · Miscellaneous Food Preparations & Kindred Products
Medifast is a U.S.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Medivir
MVIR · Health Care
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases.
Päivitetty: 28.9.2026